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A longitudinal study in 2004 and 2005 detected polyo-
maviruses WU and KI in 44% and 17% of children with and 
without respiratory symptoms, respectively, in the Nether-
lands. In some children both viruses were detected for long 
periods. In several symptomatic children no other respira-
tory pathogen was detected.
H
igh-throughput sequencing techniques have revealed 
2 new polyomaviruses called the WU virus (WUPyV) 
(1) and KI virus (KIPyV) (2). WUPyV and KIPyV have 
been reported in respiratory samples of uncontrolled stud-
ies of small groups of hospitalized patients (1–5). Howev-
er, the clinical relevance of these viruses in humans is un-
clear because data are lacking on these viruses in otherwise 
healthy persons outside a hospital setting (6–8). Whether 
these newly identiﬁ  ed viruses also occur in healthy chil-
dren and whether they should be seen as causative agents 
for clinical respiratory disease are not known. This study 
determined the prevalence of WUPyV and KIPyV in young 
children in the Netherlands with and without clinical respi-
ratory symptoms.
The Study
During a 6-month period (November 2004–April 
2005), we performed a systematic survey on WUPyV and 
KIPyV and closely monitored respiratory symptoms in a 
prospective longitudinal cohort of 18 young children (<1–7 
years of age, mean age 3.4 years from throughout the Neth-
erlands). The study coordinator contacted parents twice a 
week (by telephone or email) to ask about the presence of 
any signs or symptoms of respiratory tract illness. Respi-
ratory signs and symptoms were deﬁ  ned as coryza (rhin-
orrhea or nasal congestion), sore throat, ear ache with or 
without ear discharge, cough, sputum production or dysp-
nea, in the presence or absence of fever (>38°C). Every 2 
weeks, samples for virus detection were collected regard-
less of any respiratory symptoms. A sample was deﬁ  ned as 
asymptomatic if the child had no respiratory symptoms 1 
full week before and 1 full week after sampling. A sample 
was deﬁ  ned as symptomatic if the child had any respira-
tory symptoms 1 week before and 1 week after sampling. 
Parents collected the samples for virus detection by rub-
bing 1 nostril and posterior oropharynx of their child with 
separate cotton-tipped swabs. Feasibility of virus sampling 
by the parents has been described earlier (9). The study was 
approved by the local medical ethics committee, and the 
parents gave written informed consent.
In total 230 samples of symptomatic and asymptomatic 
samples were collected and tested for WUPyV and KIPyV 
by real-time PCR using an ABI 7500 System (Applied Bio-
systems, Foster City, CA, USA) (10) and for other respi-
ratory pathogens by PCR (11) (Figure 1). In 119 samples 
(52%), the following nonpolyomavirus respiratory patho-
gens were detected: rhinovirus (32%); enterovirus (3%); 
respiratory syncytial viruses A and B (2%); coronaviruses 
OC43, 229E, and NL63 (17%); inﬂ  uenza viruses A and B 
(1%); human metapneumovirus (1%); adenovirus (<1%); 
Mycoplasma pneumoniae (3%); and Chlamydophila pneu-
moniae (5%).
WUPyV was found in 21 (9%) of 230 samples from 
8 (44%) of 18 children (Figure 1). In 5 episodes WUPyV 
was the only pathogen detected and might therefore have 
been responsible for the observed respiratory symptoms. 
KIPyV was found in 6 (3%) of 230 samples in 3 (17%) of 
18 children. In 2 symptomatic samples positive for KIPyV, 
no other pathogens were detected.
To track possible reinfections and/or prolonged infec-
tions of WUPyV and KIPyV during the observation period, 
we constructed Figure 2. For pediatric patients 1, 2, 3, and 
6, WUPyV was found in >1 positive sample. In addition, 
prolonged presence of WUPyV (in >2 successive samples, 
equal to >2 weeks) was detected in 3 children (1, 2, and 6). 
The youngest child of the group (patient 1) had 2 periods of 
a prolonged infection with WUPyV (1 period of 3 succes-
sive positive samples and 1 period with 4 positive samples) 
as well as 3 successive KIPyV-positive samples. In the oth-
er children, KIPyV positivity was limited to 1 period.
Most infections with WUPyV and KIPyV were seen in 
the youngest children; 95% of the WUPyV infections and 
83% of the KIPyV infections were seen in children <4 years 
of age (patients 1–10). For the children with a WUPyV in-
fection, the median age was 2.6 years (interquartile range 
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Conclusions
This unique prospective longitudinal cohort study 
shows a high occurrence of WUPyV and KIPyV in chil-
dren. WUPyV and KIPyV were repeatedly observed as the 
only detectable pathogen in children with respiratory symp-
toms, which may suggest that both viruses have pathogenic 
potential. In addition, younger age was associated with a 
higher occurrence of WUPyV and KIPyV infections.
Our overall percentages of WUPyV and KIPyV are 
somewhat higher than percentages reported in most other 
studies (1–8). This ﬁ  nding may partially be explained by 
the fact that samples were collected during the respiratory 
disease season. In addition, our study had a longitudinal 
design, and, therefore, our prevalences cannot be com-
pared with those of other studies. In our study WUPyV was 
the third most prevalent pathogen (9%) after rhinoviruses 
(32%) and coronaviruses (17%). KIPyV was the ﬁ  fth most 
prevalent pathogen (3%), comparable with enteroviruses. 
The pathogenic role of WUPyV and KIPyV in respi-
ratory disease is a subject of dispute. Some researchers 
suggest an association between WUPyV and KIPyV and 
respiratory symptoms (1,3,5), whereas others question the 
association between these viruses and disease (7,8). Here 
we report that WUPyV and KIPyV were the only viruses 
found in several samples, most of them originating from 
symptomatic episodes. Although these ﬁ  ndings suggest a 
pathogenic role for both viruses, more extensive data are 
needed to establish their deﬁ  nite role in respiratory disease. 
In addition, we stress that we did not look for parainﬂ  u-
enza virus, human bocavirus, and coronavirus HKU1 in our 
study. We cannot exclude the fact that these viruses might 
be present in the samples in which only KIPyV or WUPyV 
was detected.
Because latent infections with subsequent asymptom-
atic reactivation are described as a feature of the polyoma-
viruses BK and JC (12), we were interested in the longi-
tudinal course of WUPyV and KIPyV infections. Because 
most previous studies have a cross-sectional design, rein-
fections and persistence of WUPyV and KIPyV are usually 
missed. One study reported that WUPyV was detected in 
sequential samples of 2 immunocompromised patients for 
6–8 weeks; 1 child was 16 months and the other 4 years of 
age (5). In the present study, positive episodes of WUPyV 
were interrupted by intervals during which no virus was 
detected in some children; however, the low viral load in 
these samples (high cycle threshold values) may have been 
below the detection limit in these negative intervals. In ad-
dition, we cannot exclude the possibility that poor collec-
tion techniques of samples with low viral loads resulted in 
failure to detect WUPyV.
We observed periods of successive positive samples 
for both WUPyV and KIPyV. These results might indi-
cate that both viruses are able to persist in the respiratory 
tract. However, these positive samples could also represent 
new infections of WUPyV and KIPyV. Genetic analysis is 
needed to investigate whether this observed persistence is 
actual persistence or whether it represents new infections 
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230 samples
165 symptomatic samples 65 asymptomatic samples
72 with no other pathogen:
•5  W U P y V
• 2 KIPyV
93 with other pathogen:
14 WUPyV
3 KIPyV
39 with no other pathogen:
•1  W U P y V
• 1 KIPyV
26 with other pathogen:
•1  W U P y V
• 0 KIPyV
Figure 1. Flow chart of the respiratory samples taken in the 
study. Samples were collected during November 2004–April 
2005, throughout the Netherlands. Samples were taken during 
symptomatic and asymptomatic episodes. Results show WU 
polyomavirus (WUPyV )and KI polyomavirus (KIPyV) detections in 
samples simultaneously negative for other respiratory pathogens 
and in samples in which >1 other respiratory pathogen(s) were 
detected.
Figure 2. Timelines of WU polyomavirus (WUPyV ) and KI 
polyomavirus (KIPyV) in 2-week samples, taken regardless of 
symptoms. Samples were collected during November 2004–April 
2005, throughout the Netherlands. Each line represents a child in 
order of increasing age (patients 1–18, aged <1–7 years); the time 
between 2 vertical lines accounts for ≈2 weeks. The solid symbols 
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with different WUPyV and KIPyV subtypes. We conclude 
that WUPyV and KIPyV are frequently present in young 
children. Additional studies are needed to conﬁ  rm the sug-
gestion from this study that both viruses may be associated 
with respiratory disease.
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From the Greek Khimaira, Latin Chimaera; she-goat. In Greek mythology: a composite creature with the body and 
head of a lion, a goat’s head rising from its back, and a serpent’s tail. In science: an individual organism whose 
body contains cell populations derived from different zygotes, of the same or different species. Each population of 
cells keeps its own character, and the resulting animal is a mixture of tissues. Chimera also refers to a substance 
created from proteins or genes of 2 species, as by genetic engineering. Chimerism is rare in humans; ≈40 cases 
have been reported.
Source:  Dorland’s illustrated medical dictionary, 31st edition. Philadelphia: Saunders; 2007; http://www.merriam-webster.com; 
http://www.medicinenet.com/script/main/hp.asp